On Tuesday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) opened higher 6.19% from the last session, before settling in for the closing price of $8.88. Price fluctuations for DAWN have ranged from $5.64 to $14.46 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -38.09%. Company’s average yearly earnings per share was noted 1.35% at the time writing. With a float of $73.53 million, this company’s outstanding shares have now reached $102.68 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Day One Biopharmaceuticals Inc is 28.38%, while institutional ownership is 72.18%. The most recent insider transaction that took place on Nov 17 ’25, was worth 38,503. In this transaction Gen Counsel & Secretary of this company sold 4,319 shares at a rate of $8.91, taking the stock ownership to the 62,626 shares. Before that another transaction happened on Nov 17 ’25, when Company’s COO and CFO sold 4,062 for $8.91, making the entire transaction worth $36,212. This insider now owns 294,715 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.63 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.35) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 86.21% during the next five years compared to -38.09% drop over the previous five years of trading.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Check out the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). In the past quarter, the stock posted a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.49, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Compared to the last year’s volume of 1.52 million, its volume of 2.75 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 35.75%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 72.08%, which indicates a significant increase from 46.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.73 in the past 14 days, which was higher than the 0.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.80, while its 200-day Moving Average is $7.57. Nevertheless, the first resistance level for the watch stands at $9.83 in the near term. At $10.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.68. If the price goes on to break the first support level at $8.97, it is likely to go to the next support level at $8.51. Should the price break the second support level, the third support level stands at $8.12.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are currently 102,676K shares outstanding in the company with a market cap of 968.23 million. Presently, the company’s annual sales total 131,160 K according to its annual income of -95,500 K. Last quarter, the company’s sales amounted to 39,800 K and its income totaled -19,730 K.
